PepGen Inc.
PEPG · XNASCIK 1835597fmd_0NT56FRMC4R2HZSSZ7B080X6CRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | 19 | 54 | 68 | 76 | 71 |
| Total operating expenses | 27 | 68 | 85 | 98 | 94 |
| Operating income | (27) | (68) | (85) | (98) | (94) |
| Interest and investment income | – | 3 | 6 | 7 | 4 |
| Other non-operating income (expense) | (0) | 3 | 6 | 7 | 4 |
| Income before taxes | (27) | (65) | (79) | (91) | (90) |
| Income tax expense | 0 | 4 | 0 | (1) | 0 |
| Net income from continuing operations | (27) | (69) | (79) | (90) | (90) |
| Net income | (27) | (69) | (79) | (90) | (90) |